Compare · DCPH vs NVO
DCPH vs NVO
Side-by-side comparison of Deciphera Pharmaceuticals Inc. (DCPH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCPH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 402.6x DCPH ($455.0M).
- NVO has hit the wire 8 times in the past 4 weeks while DCPH has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 18 for DCPH).
- Company
- Deciphera Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $455.0M
- $183.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 18
- 25
Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DCPH
- SEC Form 15-12G filed by Deciphera Pharmaceuticals Inc.
- SEC Form EFFECT filed by Deciphera Pharmaceuticals Inc.
- EVP & Chief Medical Officer Sherman Matthew L was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Kelly Thomas Patrick was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP, Chief Development Officer Pitman Jama was granted 20,163 shares and returned 53,951 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Friedman Franklin Stuart closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Kelley Susan L.
- EVP & Chief Scientific Officer Dhanak Dashyant was granted 25,913 shares and returned 184,088 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Martin John Richard
- Chief Commercial Officer Martin Daniel C. was granted 20,163 shares and returned 43,951 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care